Treatment options for patients with renal cell carcinoma (RCC) have expanded, especially with the development of immunotherapy. Despite this increase in therapeutic agents, there continues to be significant research interest developing new treatments as well as vaccines, as approximately one-third of patients with localized RCC will eventually develop metastatic disease despite surgical resection of the primary tumor.1

Vaccine development has been challenging based on multiple factors: optimizing target antigens, ineffective adjuvant therapies, drug delivery failures, and complex pathophysiology that has yet to be fully elucidated.2 RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells (DCs), genetically modified tumor cells, and peptides.3

One unique target within RCC is carbonic-anhydrase IX (CA IX) which is a hypoxia-inducible tumor antigen found on the cell surface membrane.1,2 CA IX is predominantly expressed in RCC cells and not in normal kidney tissue, as well as limited organ system distribution outside of the kidneys (stomach, pancreaticobiliary system, and proximal bowel)4,5.

As previously noted, the pathogenesis of RCC is complex, however 1 pathway includes inactivation of the von Hippel-Lindau (VHL) gene, resulting in impaired VHL protein (pVHL).1 This subsequently leads to an upregulation and accumulation of hypoxia-inducible factors (HIFs). The imbalance between defective pVHL and increased HIF levels further induce HIF-regulated proteins including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and CA IX.1 All of these HIF-regulated proteins lead to increased angiogenesis, invasion, and overall tumor growth.1


Continue Reading

Specifically, CA IX helps regulate pH and promote tumor cell survival in hypoxic environments.2 Additionally, CA IX can be recognized by the immune system via T cells interacting with the major histocompatibility complex (MHC) class I and II.2 Therefore, its role within the tumor microenvironment (TME) is critical in the development and progression of RCC.

Based on its implication in multiple pathways within RCC including specificity, immunogenicity, and pathogenesis, there have been early studies aimed at developing a vaccine targeting CA IX.2 These studies have provided mixed results, and have yet to provide the results expected based on its overall clinical profile.

A research group led by Faiena and colleagues recently developed a DC-based vaccine targeting CA IX using immature DCs and granulocyte-macrophage (GM) colony stimulating factor (CSF) which is delivered by an adenoviral vector (Ad) (DC-AdGMCA IX).2 The authors evaluated this vaccine in an open-label phase 1 escalation study and published their findings in the Journal of Immunotherapy.